Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: Synthesis, stability, and stereochemical requirements for enzymatic cleavage

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 2, 2007, Pages 517-521

  Jiang, Yongying ^a   Hu, Longqin ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

4 Aminocyclophosphamide; Anticancer prodrugs; Cyclophosphamide; gem Diamines; Phosphoramide mustard; Proteolytic activation; Site specific activation

Indexed keywords

4 AMINOCYCLOPHOSPHAMIDE; BUFFER; CHYMOTRYPSIN A; CYCLOPHOSPHAMIDE DERIVATIVE; PHENYLALANINE DERIVATIVE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMATOGRAPHY; DIASTEREOISOMER; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOMER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEIN DEGRADATION; SPECTROSCOPY; STEREOCHEMISTRY;

ANTINEOPLASTIC AGENTS; CHYMOTRYPSIN; DRUG DESIGN; DRUG STABILITY; ENZYME ACTIVATORS; HALF-LIFE; MOLECULAR CONFORMATION; PEPTIDE HYDROLASES; PHENYLALANINE; PHOSPHORAMIDE MUSTARDS; PRODRUGS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846058984     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.017     Document Type: Article

References (33)

1. Eltahir A., Heys S.D., Hutcheon A.W., Sarkar T.K., Smith I., Walker L.G., Ah-See A.K., and Eremin O. Am. J. Surg. 175 (1998) 127
2. Young S.D., and Hill R.P. J. Natl. Cancer Inst. 82 (1990) 371
3. Sinhababu A.K., and Thakker D.R. Adv. Drug Delivery Rev. 19 (1996) 241
4. Dubowchik G.M., and Walker M.A. Pharmacol. Ther. 83 (1999) 67
5. Hu L. IDrugs 7 (2004) 736
6. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., and Schmitt M. Int. J. Oncol. 13 (1998) 893
7. de Groot F.M., van Berkom L.W., and Scheeren H.W. J. Med. Chem. 43 (2000) 3093
8. Eisenbrand G., Lauck-Birkel S., and Tang W.C. Synthesis (1996) 1246
9. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., and Engler J.A. Crit. Rev. Oral. Biol. Med. 4 (1993) 197
10. Ray J.M., and Stetler-Stevenson W.G. Eur. Respir. J. 7 (1994) 2062
11. Denmeade S.R., Nagy A., Schally A., and Issacs J.T. Proc. Am. Assoc. Cancer Res. 39 (1998) 3765
12. Coombs G.S., Bergstrom R.C., Pellequer J.L., Baker S.I., Navre M., Smith M.M., Tainer J.A., Madison E.L., and Corey D.R. Chem. Biol. 5 (1998) 475
13. Colvin O.M. Curr. Pharm. Des. 5 (1999) 555
14. Borch R.F., and Canute G.W. J. Med. Chem. 34 (1991) 3044
15. Li Z., Han J., Jiang Y., Browne P., Knox R.J., and Hu L. Bioorg. Med. Chem. 11 (2003) 4171
16. Foster E.L. J. Pharm. Sci. 67 (1978) 709
17. Hernick M., and Borch R.F. J. Med. Chem. 46 (2003) 148
18. Jiang Y., Han J., Yu C., Vass S.O., Searle P.F., Browne P., Knox R.J., and Hu L. J. Med. Chem. 49 (2006) 4333
19. Hu L., Yu C., Jiang Y., Han J., Li Z., Browne P., Race P.R., Knox R.J., Searle P.F., and Hyde E.I. J. Med. Chem. 46 (2003) 4818
20. Borch R.F., and Millard J.A. J. Med. Chem. 30 (1987) 427
21. Kwon C.H. Arch. Pharm. Res. 22 (1999) 533
22. Cox P.J. Biochem. Pharmacol. 28 (1979) 2045
23. Loudon G.M., Almond M.R., and Jacob J.N. J. Am. Chem. Soc. 103 (1981) 4508
24. Fletcher M.D., and Campbell M.M. Chem. Rev. 98 (1998) 763
25. Manolopoulou A.P.C., and Tsegenidis T. Eur. J. Med. Chem. 27 (1992) 949
26. Loudon G.M., Radhakrishna A.S., Almond M.R., Blodgett J.K., and Boutin R.H. J. Org. Chem. 49 (1984) 4272
27. Pallai P., and Goodman M. J. Chem. Soc., Chem. Commun. (1982) 280
28. Yu C., Jiang Y., Liu B., and Hu L. Tetrahedron Lett. 42 (2001) 1449
29. Walsh S.P., and Shulman-Roskes E.M. J. Labelled Compd. Radiopharm. 36 (1995) 1193
30. Martinek T., Forro E., Gunther G., Sillanpaa R., and Fulop F. J. Org. Chem. 65 (2000) 316
31. Shih Y.E., Wang J.S., and Chen C.T. Heterocycles 9 (1978) 1277
32. Boyd V.L., Zon G., Himes V.L., Stalick J.K., Mighell A.D., and Secor H.V. J. Med. Chem. 23 (1980) 372
33. Neurath H., and Schwert G.W. Chem. Rev. 46 (1950) 69